Financial Summary (All financials)
| In millions, except per share items | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 |
| Revenues | 18.6 | 0.0 | 0.0 | 0.0 | 20.4 |
| Revenue growth | | | | -100.0% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 20.4 |
| Gross profit | 18.6 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | 100.0% | | | | 0.0% |
| Selling, general and administrative | 103.1 | 27.9 | 11.9 | | |
| Research and development | 93.3 | 50.2 | 59.0 | 36.1 | |
| General and administrative | | | | 7.3 | 5.2 |
| EBIT | -177.7 | -78.3 | -70.9 | -43.3 | -25.5 |
| EBIT margin | -958.2% | | | | -125.4% |
| Pre-tax income | -178.7 | -79.9 | -73.8 | -43.7 | -25.8 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -178.7 | -79.9 | -81.2 | -62.4 | 0.0 |
| Net margin | -963.4% | | | | -0.1% |
| |
| Diluted EPS | ($4.39) | ($2.43) | ($22.42) | ($205.45) | ($104.33) |
| Shares outstanding (diluted) | 40.7 | 32.8 | 3.6 | 0.3 | 0.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|